Definition of Virologic Response and the Type of Assay Used for Quantification of Viral Load May Influence the Proportion of Responders to Antiretroviral Therapy

Moing, Vincent Le; Chêne, Geneviève; Masquelier, Bernard; Sicard, Didier; Brun-Vézinet, F; Reynes, Jacques; Raffi, F.

doi:10.1097/00042560-200005010-00016

Cited by 5 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The threshold of 1000 copies/mL was chosen to overcome the heterogeneity in detection limits of assays used to quantify plasma HIV-1 RNA in the different hospitals. 18 In models 3 and 4, the CD4 cell count and plasma HIV-1 RNA level attained at 6 months were used as log-transformed continuous variables or as 4 categories ($350, 200-349, 100-199, and ,100 CD4 cells/mL and ,3, 3-3.9, 4-4.9, and $5 log 10 HIV-1 RNA copies/mL). 12 In model 5, the response was classified as complete, immunologic response only, virologic response only, and absent based on whether 50 or more CD4 cells/mL had been gained and whether the HIV-1 RNA level declined by at least 1 log 10 or became undetectable (,1000 copies/mL).…”

Section: Prognostic Modelsmentioning

confidence: 99%

Response to Highly Active Antiretroviral Therapy at 6 Months and Long-Term Disease Progression in HIV-1 Infection

Grabar

Moing²,

Goujard³

et al. 2005

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

show abstract

Section: Prognostic Modelsmentioning

confidence: 99%

Response to Highly Active Antiretroviral Therapy at 6 Months and Long-Term Disease Progression in HIV-1 Infection

Grabar

Moing²,

Goujard³

et al. 2005

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

show abstract

Viral Load as a Primary Outcome in Human Immunodeficiency Virus Trials

Journot

Chêne

Joly

et al. 2001

Controlled Clinical Trials

View full text Add to dashboard Cite

Impact of Discontinuation of Initial Protease Inhibitor Therapy on Further Virological Response in a Cohort of Human Immunodeficiency Virus–Infected Patients

et al. 2002

View full text Add to dashboard Cite

Although discontinuation of antiretroviral drug therapy is common, the impact on outcome in routine clinical practice is unknown. The Antiprotéases Cohorte (APROCO) Cohort Study enrolled 1281 patients at the time they started a protease inhibitor (PI)-containing regimen from 1997 through 1999. After a median duration of follow-up of 20 months, 51% of patients had discontinued their initial PI. Prospectively recorded reasons for discontinuation were intolerance (52% of patients), poor adherence (22%), and failure of therapy (15%). In a multivariate logistic regression analysis, only discontinuation due to poor adherence was associated with a lower frequency of human immunodeficiency virus RNA level in plasma of <500 copies/mL 12 months after initiation of therapy (odds ratio, 0.27 vs. no change; P<.0001); discontinuation due to intolerance was not associated with virological response (odds ratio, 0.89; P=.58). Patients experiencing intolerance should be reassured that changing therapy will probably not be harmful. Multidisciplinary efforts should concentrate on ways to avoid discontinuation of treatment for adherence reasons.

show abstract

Definition of Virologic Response and the Type of Assay Used for Quantification of Viral Load May Influence the Proportion of Responders to Antiretroviral Therapy

Cited by 5 publications

References 6 publications

Response to Highly Active Antiretroviral Therapy at 6 Months and Long-Term Disease Progression in HIV-1 Infection

Response to Highly Active Antiretroviral Therapy at 6 Months and Long-Term Disease Progression in HIV-1 Infection

Viral Load as a Primary Outcome in Human Immunodeficiency Virus Trials

Impact of Discontinuation of Initial Protease Inhibitor Therapy on Further Virological Response in a Cohort of Human Immunodeficiency Virus–Infected Patients

Contact Info

Product

Resources

About